News Snapshot:
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing on March 16, 2020. [Photo/Xinhua] LONDON — A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomised clinical trial published Thursday in The Lancet Infectious Diseases journal. The latest study included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients. Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all...
